About the Journal
Aims and Scope
The British Journal of Cancer is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research. It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention, diagnosis and treatment.
BJC welcomes research across all cancer types and has a particular focus on: metastasis, microenvironment, immunology and immunotherapy, targeted and next-generation therapeutics, chemotherapy and radiotherapy, mechanisms of resistance, clinical trials, genomics, epigenomics and precision medicine, epidemiology, metabolism and state-of-the art diagnostic approaches.
The British Journal of Cancer is owned by Cancer Research UK, the world’s leading independent cancer charity dedicated to saving lives through research.
The journal is separated into six general categories:
- Clinical Studies
- Translational Therapeutics
- Molecular Diagnostics
- Genetics and Genomics
- Cellular and Molecular Biology
To explore the type of articles that BJC publishes, please browse our subject pages.
Submit your next manuscript to BJC and benefit from:
- International and highly respected editorial team
- Rapid decision and publication times
- Wide exposure and article visibility via nature.com
- Funder-compliant open access options available
- Owned by Cancer Research UK, the world’s leading independent cancer charity dedicated to saving lives through research
- Engaged and growing Twitter following for BJC at @BrJCancer
- Share your article through SharedIt: Springer Nature’s content-sharing initiative allowing authors and subscribers to share links to view-only, full-text articles from this journal
Article-level metrics such as number of downloads, citations and online attention provide an overview of the attention received by a paper, and are available from each article page.
The 2019 peer review performance metrics for British Journal of Cancer are shown below:
Average time to decision without external review - 7 days
Average time to decision following external review - 53 days
Average time from submission to acceptance - 146 days
Average time from acceptance to publication - 18 days
Article page views - 1,845,907
Altmetric mentions - 3,992
The 2019 journal metrics* for British Journal of Cancer are as follows:
2-year Impact Factor: 5.791
5-year Impact Factor: 6.210
Immediacy index: 1.299
Eigenfactor® score: 0.05156
Article influence score: 1.800
*2019 Journal Citation Reports® Science Edition (Clarivate Analytics, 2020)
For more information on these journal metrics, please visit this link
Adrian L Harris
University of Oxford, UK
Cancer Research UK
BJC Main Editorial Office
Cancer Research UK
2 Redman Place
London E20 1JQ
Tel: +44 (0)20 3469 6076
ISSN and eISSN
The international standard serial number (ISSN) for BJC is 0007-0920, and the electronic international standard serial number (eISSN) is 1532-1827.
24 issues a year
BJC is abstracted/indexed in the following:
EBSCO Discovery Service
Science Citation Index
Science Citation Index Expanded (SciSearch)
Current Contents / Clinical Medicine
Current Contents / Life Sciences
Summon by ProQuest
EBSCO Academic Search
EBSCO Advanced Placement Source
EBSCO Biomedical Reference Collection
EBSCO STM Source
EBSCO TOC Premier
British Journal of Cancer now provides its latest table of contents as an RSS web feed. This allows users with an RSS reader to receive automatic updates whenever new content is added to these pages.
Receive British Journal of Cancer's current issue table of contents.
Find out more about RSS feeds, how to download an RSS reader and see all the news feeds offered by Springer Nature.